MCID: PRT058
MIFTS: 65

Pure Autonomic Failure

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pure Autonomic Failure

MalaCards integrated aliases for Pure Autonomic Failure:

Name: Pure Autonomic Failure 54 60 56 74
Orthostatic Hypotension 54 26 55 30 17
Idiopathic Orthostatic Hypotension 54 60 74
Bradbury-Eggleston Syndrome 54 55 60
Postural Hypotension 26 55
Bradbury Eggleston Syndrome 54
Pure Idiopatic Dysautonomia 60
Hypotension, Orthostatic 26
Hypotension Orthostatic 56
Hypotension, Postural 26
Pure Dysautonomia 60
Paf 60

Characteristics:

Orphanet epidemiological data:

60
pure autonomic failure
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

ICD10 34 I95.1
MESH via Orphanet 46 C544351 D054970
ICD10 via Orphanet 35 G90.3
UMLS via Orphanet 75 C0393911 C2931939
Orphanet 60 ORPHA441

Summaries for Pure Autonomic Failure

NIH Rare Diseases : 54 Pure autonomic failure (PAF) is a neurodegenerative disease of the autonomic nervous system, which regulates involuntary body processes such as blood pressure and breathing rate. PAF affects only the peripheral autonomic nervous system, which means it does not involve the brain and spinal cord (the central nervous system). It usually begins in midlife, although it can begin earlier. The main symptom of PAF is orthostatic hypotension, a sudden drop in blood pressure upon standing. This causes a person to feel dizzy and lightheaded, requiring them to sit or lie down to prevent fainting. People with PAF also have an abnormal blood pressure response to other common daily activities or exposures, as well as additional symptoms affecting various body systems. The reason that PAF develops is not known. It is not known to be inherited. The symptoms are caused by abnormal accumulations of protein, called Lewy bodies, in the cells of autonomic nerves. The Lewy bodies restrict the production and release of norepinephrine from nerve cells, which in turn causes hypotension. Diagnosing PAF may involve tilt table testing, 24-hour blood pressure monitoring, hyperventilation testing, and a norepinephrine blood test. Treatment options do not stop disease progression but help to control symptoms. Options may include avoiding triggers of symptoms, increasing fluid and salt intake, using compressive garments, and/or various medications. PAF usually has a slowly progressive course and may result in a person being restricted to a reclined position in their home.

MalaCards based summary : Pure Autonomic Failure, also known as orthostatic hypotension, is related to multiple system atrophy 1 and amyloidosis, hereditary, transthyretin-related. An important gene associated with Pure Autonomic Failure is DBH (Dopamine Beta-Hydroxylase), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Circadian entrainment. The drugs Naltrexone and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include heart, spinal cord and brain, and related phenotypes are anhidrosis and orthostatic hypotension

Genetics Home Reference : 26 Orthostatic hypotension is a drop in blood pressure that occurs when moving from a laying down (supine) position to a standing (upright) position. The word "orthostasis" means to stand up, so the condition is defined as low blood pressure (hypotension) that occurs upon standing.

NINDS : 55 Orthostatic hypotension is a sudden fall in blood pressure that occurs when a person assumes a standing position. It is due to a lesion of the baroreflex loop, which senses a change in blood pressure and adjusts heart rate and activates sympathetic nerve system fibers to cause the blood vessels to narrow and correct blood pressure. It may also be caused by hypovolemia (a decreased amount of blood in the body), resulting from the excessive use of diuretics, vasodilators, or other types of drugs, dehydration, or prolonged bed rest. The disorder may be associated with Addison's disease, diabetes, and certain neurological disorders including Multiple System Atrophy with Orthostatic Hypotension (formerly known as Shy-Drager syndrome), autonomic system neuropathies, and other dysautonomias. Symptoms, which generally occur after sudden standing, include dizziness, lightheadedness, blurred vision, and syncope (temporary loss of consciousness).

Wikipedia : 77 Pure autonomic failure (PAF) is a form of dysautonomia that first occurs in middle age or later in life;... more...

Related Diseases for Pure Autonomic Failure

Diseases related to Pure Autonomic Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 multiple system atrophy 1 33.0 DBH SNCA TH
2 amyloidosis, hereditary, transthyretin-related 32.7 DBH TTR
3 syncope 30.8 GNB3 NPPA
4 pulmonary edema 30.4 ACE NPPA REN
5 movement disease 30.3 DDC SNCA TH
6 congestive heart failure 30.1 ACE EPO NPPA REN
7 rem sleep behavior disorder 30.0 ACHE SNCA
8 cerebrovascular disease 29.9 ACE ACHE REN
9 pheochromocytoma 29.9 DBH DDC MAOB REN TH
10 chronic kidney failure 29.8 ACE EPO NPPA REN TTR
11 kidney disease 29.8 ACE EPO NPPA REN TTR
12 aortic coarctation 29.7 ACE GNB3
13 hypertension, essential 29.5 ACE DBH GNB3 NEDD4L NPPA REN
14 myocardial infarction 29.4 ACE GNB3 NPPA PDE5A REN
15 parkinson disease, late-onset 29.1 ACHE DBH DDC MAOA MAOB SNCA
16 orthostatic hypotension 2 12.8
17 multiple system atrophy with orthostatic hypotension 12.6
18 orthostatic hypotensive disorder, streeten type 12.6
19 orthostatic hypotension 1 12.5
20 dopamine beta-hydroxylase deficiency 11.7
21 primary orthostatic hypotension 11.7
22 autoimmune autonomic ganglionopathy 11.6
23 dysautonomia 11.5
24 platelet-activating factor acetylhydrolase deficiency 11.3
25 achalasia-addisonianism-alacrima syndrome 11.3
26 syncope, familial vasovagal 11.3
27 autonomic peripheral neuropathy 11.3
28 neuropathy, hereditary sensory and autonomic, type iii 11.2
29 brain dopamine-serotonin vesicular transport disease 11.2
30 neuropathy - hereditary 11.2
31 orthostatic intolerance 11.0
32 postural orthostatic tachycardia syndrome 10.9
33 spinal cord injury 10.6
34 neuropathy 10.5
35 autonomic neuropathy 10.4
36 hereditary dystonia 10.4 DBH TH
37 gastroesophageal reflux 10.4
38 aging 10.4
39 rere-related disorders 10.4
40 depression 10.4
41 renal artery obstruction 10.4 ACE REN
42 hypertension, diastolic 10.3 ACE REN
43 supratentorial primitive neuroectodermal tumor 10.3 DDC TH
44 hypertensive retinopathy 10.3 ACE REN
45 orthostatic proteinuria 10.3 ACE REN
46 chronic fatigue syndrome 10.3
47 malignant essential hypertension 10.3 ACE REN
48 anterolateral myocardial infarction 10.3 ACE NPPA
49 anuria 10.3 ACE REN
50 pernicious anemia 10.3

Graphical network of the top 20 diseases related to Pure Autonomic Failure:



Diseases related to Pure Autonomic Failure

Symptoms & Phenotypes for Pure Autonomic Failure

Human phenotypes related to Pure Autonomic Failure:

60 33 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anhidrosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000970
2 orthostatic hypotension 60 33 hallmark (90%) Very frequent (99-80%) HP:0001278
3 abnormality of circulating catecholamine level 60 33 hallmark (90%) Very frequent (99-80%) HP:0012099
4 constipation 60 33 frequent (33%) Frequent (79-30%) HP:0002019
5 urinary incontinence 60 33 frequent (33%) Frequent (79-30%) HP:0000020
6 syncope 60 33 frequent (33%) Frequent (79-30%) HP:0001279
7 dysuria 60 33 frequent (33%) Frequent (79-30%) HP:0100518
8 impotence 60 33 occasional (7.5%) Occasional (29-5%) HP:0000802
9 dysautonomia 60 Very frequent (99-80%)
10 constitutional symptom 60 Very frequent (99-80%)

MGI Mouse Phenotypes related to Pure Autonomic Failure:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ACE ACHE DBH DDC EPO MAOA
2 cardiovascular system MP:0005385 10.11 ACE DBH DDC EPO MAOA NEDD4L
3 behavior/neurological MP:0005386 10.1 ACE ACHE DBH DDC MAOA MAOB
4 mortality/aging MP:0010768 9.96 ACE ACHE DBH DDC EPO GNB3
5 nervous system MP:0003631 9.85 ACHE DBH DDC GNB3 MAOA MAOB
6 renal/urinary system MP:0005367 9.56 ACE DDC MAOB NEDD4L NPPA REN
7 vision/eye MP:0005391 9.1 ACHE DBH DDC GNB3 TH TTR

Drugs & Therapeutics for Pure Autonomic Failure

Drugs for Pure Autonomic Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 379)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
2
Ethanol Approved Phase 4 64-17-5 702
3
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
5
Droxidopa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23651-95-8 443940
6
Losartan Approved Phase 4,Phase 1 114798-26-4 3961
7
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198
8
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
9
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 1 58-93-5 3639
10
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1 59-92-7 6047
11
Mirabegron Approved Phase 4,Phase 2 223673-61-8 9865528
12
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
16
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
17
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
18
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
19
Prednisone Approved, Vet_approved Phase 4,Not Applicable 53-03-2 5865
20
Celecoxib Approved, Investigational Phase 4,Phase 1 169590-42-5 2662
21
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
22
Methylphenidate Approved, Investigational Phase 4,Phase 1 113-45-1 4158
23
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106133-20-4 129211
24
Naloxone Approved, Vet_approved Phase 4,Phase 2 465-65-6 5284596
25
Diazoxide Approved Phase 4 364-98-7 3019
26
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
27
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
28
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
29
Silodosin Approved Phase 4,Phase 3 160970-54-7
30
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-70-2 271
31 Narcotics Phase 4,Phase 3,Phase 2,Not Applicable
32 Narcotic Antagonists Phase 4,Phase 2
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 1
35 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Anticonvulsants Phase 4,Phase 2,Phase 1
43 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 1
44 Bromides Phase 4,Phase 2,Phase 1
45 Pyridostigmine Bromide Phase 4,Phase 2,Phase 1 101-26-8
46 Cholinergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
47 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Not Applicable
48 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 diuretics Phase 4,Phase 3,Phase 2,Phase 1
50 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 269)
# Name Status NCT ID Phase Drugs
1 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
2 A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial) Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
3 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
4 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
5 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
6 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Completed NCT03350659 Phase 4 Midodrine;Atomoxetine
7 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
8 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
9 Comparision of Blood Pressure Variability Between Amlodipine and Losartan Completed NCT01964079 Phase 4 Amlodipine;Losartan
10 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
11 Mirabegron in Parkinson Disease and Impaired Cognition Completed NCT02536976 Phase 4 mirabegron;Placebo
12 AMISH : Aprovel for Management of Isolated Systolic Hypertension Completed NCT00264212 Phase 4 irbesartan and irbesartan-hydrochlorothiazide
13 Adjuvant Analgesic Effects of Low Dose Tramadol/Acetaminophen Combination After Open Gynaecological Surgery Completed NCT00942565 Phase 4 tramadol/acetaminophen;acetaminophen
14 Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc Completed NCT00853840 Phase 4 Maraviroc;Vardenafil;Maraviroc;Placebo
15 A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients Completed NCT00406848 Phase 4 duloxetine hydrochloride;placebo
16 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
17 Moxonidine for Prevention of Post-ablation AFib Recurrences Completed NCT01791699 Phase 4 Moxonidine;Placebo
18 Short-term Prednisone to Treat STA Study(SPTSS) Completed NCT01837433 Phase 4 Prednisone 1 week;Prednisone 6 weeks
19 Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) Recruiting NCT03608163 Phase 4 Naloxone;Diazoxide;Placebo (for Naloxone);Placebo (for Diazoxide)
20 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
21 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
22 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Recruiting NCT03229174 Phase 4 Droxidopa;Placebo
23 TQL-block for Laparoscopic Hemicolectomy Recruiting NCT03570541 Phase 4 Ropivacaine;Acetaminophen;Morphine;Saline
24 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
25 3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty Recruiting NCT03948386 Phase 4 isobaric bupivacaine;hyperbaric bupivacaine;isobaric mepivacaine
26 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
27 The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. Terminated NCT01244269 Phase 4 Methylphenidate;Methylphenidate;Placebo 10;Placebo 20
28 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
29 Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA Unknown status NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
30 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
31 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
32 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
33 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
34 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
35 Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty Completed NCT01707953 Phase 3 Midodrine;Placebo
36 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
37 Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Completed NCT02445898 Phase 2, Phase 3 Methylprednisolone;Isotonic Sodium Chloride
38 Exhaled Levels of Nitric Oxide Completed NCT00753948 Phase 2, Phase 3 N-Nitro L-arginine-methylester (L-NAME)
39 Efficacy and Safety of Primovist in Chinese Patients Completed NCT00526188 Phase 3 Gadoxetic Acid Disodium (Primovist, BAY86-4873)
40 Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee Completed NCT02697773 Phase 3
41 Deambulatory Epidural During the Labour Completed NCT02264834 Phase 3 Levobupivacaine 0.1% + Sufentanil 0.2µg/ml;Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
42 A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3 Dapagliflozin;Placebo matching Dapagliflozin
43 Prevention of Low Blood Pressure in Persons With Tetraplegia Completed NCT00237770 Phase 2, Phase 3 N-Nitro L-arginine-methylester (L-NAME)
44 Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301) Completed NCT00446524 Phase 3 Valsartan + Amlodipine besilate
45 LEPU Renal Denervation System for Resistant Hypertension Completed NCT02536326 Phase 3
46 A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed NCT00528879 Phase 3 Dapagliflozin;Placebo;Metformin
47 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
48 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
49 Xenazine in Late Dyskinetic Syndrome With Neuroleptics Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
50 Caffeine as a Therapy for Parkinson's Disease Completed NCT01738178 Phase 3 Caffeine;Placebo

Search NIH Clinical Center for Pure Autonomic Failure

Genetic Tests for Pure Autonomic Failure

Genetic tests related to Pure Autonomic Failure:

# Genetic test Affiliating Genes
1 Orthostatic Hypotension 30

Anatomical Context for Pure Autonomic Failure

MalaCards organs/tissues related to Pure Autonomic Failure:

42
Heart, Spinal Cord, Brain, Testes, Kidney, Skin, Prostate

Publications for Pure Autonomic Failure

Articles related to Pure Autonomic Failure:

(show top 50) (show all 1537)
# Title Authors Year
1
Editors' note: The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. ( 30936232 )
2019
2
Reader response: The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. ( 30936233 )
2019
3
Author response: The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. ( 30936234 )
2019
4
Reader response: The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. ( 30936235 )
2019
5
Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. ( 31088188 )
2019
6
Editors' note: Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. ( 30962299 )
2019
7
Reader response: Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. ( 30962300 )
2019
8
Reader response: Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. ( 30962301 )
2019
9
Author response: Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. ( 30962302 )
2019
10
Orthostatic Hypotension in Asymptomatic Patients with Chronic Kidney Disease. ( 31009994 )
2019
11
Heart Rate Variability in Spinal Cord Injury: asymptomatic orthostatic hypotension is a confounding variable. ( 30904574 )
2019
12
Increasing Prevalence of Orthostatic Hypotension as a Cause of Syncope With Advancing Age and Multimorbidity. ( 30926410 )
2019
13
What do we really know about supine hypertension in patients with orthostatic hypotension. ( 31021876 )
2019
14
Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. ( 30882602 )
2019
15
Association of Orthostatic Hypotension Timing with Clinical Events in Adults with Diabetes and Hypertension: Results from the ACCORD Trial. ( 30715100 )
2019
16
Relationships between orthostatic hypotension, frailty, falling and mortality in elderly care home residents. ( 30866845 )
2019
17
Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. ( 30229336 )
2019
18
Cerebellar impairment during an orthostatic challenge in patients with neurogenic orthostatic hypotension. ( 30527385 )
2019
19
Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension. ( 30535274 )
2019
20
Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. ( 30571543 )
2019
21
Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease. ( 30627953 )
2019
22
Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. ( 30730771 )
2019
23
Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension. ( 30798661 )
2019
24
Six-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension. ( 30949555 )
2019
25
Chemical pharmacotherapy for the treatment of orthostatic hypotension. ( 30376728 )
2019
26
Orthostatic hypotension in internal medicine wards. ( 30411636 )
2019
27
Screening for orthostatic hypotension using home blood pressure measurements. ( 30418320 )
2019
28
Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis. ( 30583909 )
2019
29
Orthostatic hypotension: is it a predictor of total and cardiovascular mortality in the elderly? ( 30640870 )
2019
30
Orthostatic hypotension and cognition in older adults: A systematic review and meta-analysis. ( 30825549 )
2019
31
Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. ( 30900378 )
2019
32
Trouble Concentrating is an Easily Overlooked Symptom of Orthostatic Hypotension in Early Parkinson's Disease. ( 30909249 )
2019
33
Association between Orthostatic Hypotension and Frailty in Hospitalized Older Patients: a Geriatric Syndrome More Than a Cardiovascular Condition. ( 30932129 )
2019
34
Orthostatic Hypotension and Falls. ( 30944921 )
2019
35
Nonpharmacologic Management of Orthostatic Hypotension in Older People: A Systematic Review. The SENATOR ONTOP Series. ( 31109911 )
2019
36
What is the relationship between frailty and orthostatic hypotension in older adults? ( 31080470 )
2019
37
Feasibility and determinants of orthostatic hypotension self-measurement at home in an elderly community-dwelling population. ( 31045224 )
2019
38
Parkinson's disease with orthostatic hypotension: analyses of clinical characteristics and influencing factors. ( 31030628 )
2019
39
Orthostatic hypotension: definition, classification and evaluation. ( 30982364 )
2019
40
Orthostatic Hypotension and Cognitive Function: Cross-sectional Results From the ELSA-Brasil Study. ( 29579161 )
2019
41
Impact of orthostatic hypotension and antihypertensive drug treatment on total and cardiovascular mortality in a very elderly community-dwelling population. ( 30063642 )
2019
42
The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. ( 30006412 )
2018
43
Third-degree atrioventricular block followed by syncope, labile hypertension, and orthostatic hypotension in a patient with nasopharyngeal cancer: baroreflex failure. ( 30038845 )
2018
44
Long-Lasting Orthostatic Hypotension and Constipation After Celiac Plexus Block; A Case Report. ( 29868459 )
2018
45
The association between orthostatic hypotension and dementia: A meta-analysis of prospective cohort studies. ( 30247788 )
2018
46
Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. ( 30045960 )
2018
47
Hypotensive Drugs and Syncope Due to Orthostatic Hypotension in Older Adults with Dementia (Syncope and Dementia Study). ( 29897099 )
2018
48
Comparison of Heart Rate Variability Parameters to the Autonomic Reflex Screen in Postural Orthostatic Tachycardia Syndrome and Neurogenic Orthostatic Hypotension. ( 29210841 )
2018
49
Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults. ( 29569329 )
2018
50
Does sympathetic dysfunction occur before denervation in pure autonomic failure? ( 29162745 )
2018

Variations for Pure Autonomic Failure

Expression for Pure Autonomic Failure

Search GEO for disease gene expression data for Pure Autonomic Failure.

Pathways for Pure Autonomic Failure

Pathways related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 DDC GNB3 MAOA MAOB NPPA SNCA
2
Show member pathways
12.86 ACHE DDC GNB3 MAOA MAOB TH
3 12.39 DBH DDC GNB3 SNCA TH
4
Show member pathways
12.09 ACE ACHE GNB3 REN
5 12.01 DDC GNB3 MAOA TH
6
Show member pathways
11.77 DDC MAOA MAOB TH
7 11.73 DDC GNB3 MAOA MAOB
8
Show member pathways
11.7 DDC MAOA MAOB
9 11.64 DDC SNCA TH
10 11.58 DBH DDC MAOA TH
11
Show member pathways
11.26 DBH DDC TH
12 11.11 MAOB SNCA TH
13
Show member pathways
11.09 ACHE DBH MAOA TH
14 11.08 DDC TH
15 11.03 DDC MAOA
16
Show member pathways
11.01 ACHE MAOA
17
Show member pathways
10.7 MAOA MAOB
18
Show member pathways
10.66 MAOA MAOB
19 10.51 ACHE DDC TH
20 10.4 DDC MAOA MAOB TH
21
Show member pathways
10.36 ACHE DBH DDC MAOA TH

GO Terms for Pure Autonomic Failure

Cellular components related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE ACHE DBH EPO NPPA REN
2 synaptic vesicle GO:0008021 9.33 DDC SNCA TH
3 extracellular space GO:0005615 9.23 ACE ACHE DBH EPO NPPA REN

Biological processes related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.98 DBH MAOA MAOB SNCA TH
2 response to drug GO:0042493 9.86 MAOB REN SNCA TH
3 response to hypoxia GO:0001666 9.81 EPO NPPA TH
4 response to lipopolysaccharide GO:0032496 9.72 EPO MAOB REN SNCA TH
5 cellular response to drug GO:0035690 9.69 DDC REN TH
6 regulation of blood pressure GO:0008217 9.67 ACE GNB3 NPPA REN
7 response to electrical stimulus GO:0051602 9.63 EPO TH
8 positive regulation of endocytosis GO:0045807 9.62 NEDD4L SNCA
9 response to immobilization stress GO:0035902 9.62 REN TH
10 response to corticosterone GO:0051412 9.61 MAOB TH
11 response to metal ion GO:0010038 9.61 NEDD4L TH
12 multicellular organism aging GO:0010259 9.6 DDC TH
13 synaptic transmission, dopaminergic GO:0001963 9.59 SNCA TH
14 amyloid-beta metabolic process GO:0050435 9.58 ACE REN
15 neurotransmitter biosynthetic process GO:0042136 9.57 ACHE TH
16 angiotensin maturation GO:0002003 9.55 ACE REN
17 cellular response to alkaloid GO:0071312 9.54 DDC TH
18 response to salt stress GO:0009651 9.52 EPO TH
19 norepinephrine biosynthetic process GO:0042421 9.49 DBH TH
20 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.48 DDC TH
21 response to pyrethroid GO:0046684 9.46 DDC TH
22 isoquinoline alkaloid metabolic process GO:0033076 9.43 DDC TH
23 dopamine biosynthetic process GO:0042416 9.43 DDC SNCA TH
24 phytoalexin metabolic process GO:0052314 9.4 DDC TH
25 neurotransmitter catabolic process GO:0042135 9.33 ACHE MAOA MAOB
26 dopamine catabolic process GO:0042420 9.13 DBH MAOA MAOB
27 catecholamine biosynthetic process GO:0042423 8.8 DBH DDC TH

Molecular functions related to Pure Autonomic Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.35 DBH MAOA MAOB SNCA TH
2 hormone activity GO:0005179 9.33 EPO NPPA TTR
3 ferrous iron binding GO:0008198 9.32 SNCA TH
4 amino acid binding GO:0016597 9.26 DDC TH
5 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB

Sources for Pure Autonomic Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....